MD Anderson and HealthEx announce collaboration to develop new platform to give patients direct control of data access
The University of Texas MD Anderson Cancer Center and HealthEx today announced a strategic collaboration aimed at developing tools for streamlining the patient consent process while also creating more transparency and control for patients in how their data is used.
As part of this collaboration, MD Anderson and HealthEx will work together for continued development and future implementation of HealthEx’s artificial...
Mailed self-collection HPV tests boost cervical cancer screening rates
Real-world study found self-collection tests were effective at increasing cervical cancer screening participation in underserved U.S. populations...
ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer
Blastic plasmacytoid dendric cell neoplasm (BPDCN) is a rare, aggressive blood cancer that often involves the bone marrow, skin and, sometimes...
ASCO: Pre-surgical combination therapy boosts survival in patients with rare thyroid cancer
A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved survival in patients with rare BRAF V600E-mutated anaplastic thyroid cancer (BRAFm-ATC) compared with historical controls, according to new research from The University of Texas MD Anderson Cancer Center.
Results from the Phase II single arm multicenter trial, presented today at the 2025 American Society of Clinical...
ASCO: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer
Approximately 8 to 12% of patients with colorectal cancer have BRAF mutations
Treatment with the triplet combination of drugs – encorafenib,...
Most Americans unaware of cancer risks associated with drinking alcohol
Alcohol is a leading preventable cause of cancer, but public awareness of the connection remains strikingly low in the U.S., with just 40%...
New biomarker may guide best use of KRAS inhibitors in lung cancer
Lung cancer patients with high TTF-1 expression had improved survival outcomes following treatment with the KRAS inhibitor, sotorasib...
ASCO: MD Anderson’s Christopher Flowers honored for teaching and mentorship
Christopher Flowers, M.D., division head of Cancer Medicine and chair of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center...
CPRIT awards over $21 million to MD Anderson for cancer research and faculty recruitment
The University of Texas MD Anderson Cancer Center today was awarded $21.4 million from the Cancer Prevention and Research Institute of Texas...